A federal judge in New Jersey signaled on June 24, 2026, that she is prepared to approve proposed settlements resolving the State’s PFAS contamination claims against 3M and the DuPont-related companies (DuPont, Chemours, and Corteva). The deals, negotiated by the New Jersey Attorney General’s office and Department of Environmental Protection, would resolve natural-resource-damage and pollution claims tied to PFAS releases at sites across the state, including the Chambers Works facility in Salem County.
What the $3 billion figure means
The figures below are public industry-wide settlements reported in the news. They are not results obtained by Quinlan Law Group or any referred co-counsel and do not predict the outcome of any individual case.
Media reports describe the combined deals as worth roughly $3 billion. That total is the aggregate of several company-specific settlements, not a single check from 3M and DuPont alone:
- 3M: up to $450 million (announced May 2025), paid over 25 years.
- DuPont, Chemours, and Corteva: up to $875 million (announced August 2025), including $225 million for natural-resource damages and $525 million for environmental abatement.
- Solvay: an earlier New Jersey settlement for Gloucester County contamination, which brings the combined total to approximately $3 billion.
The 3M and DuPont agreements are embodied in Judicial Consent Orders and remain subject to final court approval.
Why this matters for Pennsylvania
New Jersey’s settlement is a state-level action and does not directly resolve individual personal-injury claims by Pennsylvania residents. But the size and structure of the deal are important data points for the broader PFAS litigation landscape:
- It confirms that state attorneys general are extracting multi-billion-dollar recoveries from PFAS manufacturers — separate from the federal AFFF multidistrict litigation (MDL 2873) in South Carolina.
- It reinforces the litigation theory that 3M, DuPont, Chemours, and Corteva bear responsibility for PFAS pollution of drinking water and natural resources, the same theory underlying many individual cancer and personal-injury claims.
- Pennsylvania has its own significant PFAS footprint — including the former Naval Air Warfare Center Warminster (Bucks County), Naval Air Station Joint Reserve Base Willow Grove and Horsham Air Guard Station (Montgomery County), and contaminated public water systems in Chester, Delaware, Bucks, and Montgomery counties — and a similar wave of individual claims continues to move forward.
What it does not do
The New Jersey deal does not pay individual Pennsylvania residents for PFAS-linked illnesses such as kidney cancer, testicular cancer, thyroid disease, or ulcerative colitis. Personal-injury compensation is pursued separately, typically through the federal AFFF MDL or coordinated state-court proceedings, based on each person’s exposure history and diagnosis.
If you were exposed in Pennsylvania
If you or a family member lived, worked, or served in an area with documented PFAS contamination and later developed a qualifying condition, you may be eligible to pursue a claim. Case reviews are free and confidential. Request a free case review →
Sources
- Law360: Judge Poised To OK NJ’s $3B PFAS Deals With 3M, DuPont (June 24, 2026) — primary reporting on the judge’s signal to approve the deals.
- NJ Office of the Attorney General: 3M settlement announcement (May 2025) — official $450 million deal summary.
- NJ Office of the Attorney General: DuPont settlement announcement (August 2025) — official over-$2 billion deal summary.
- NJDEP: 3M PFAS Settlement and NJDEP: DuPont/Chemours PFAS Settlement — official deal documents and payment schedules.
- The Philadelphia Inquirer: DuPont part of up to $2B PFAS settlement in N.J. (August 4, 2025) — explains how the 3M, DuPont, and Solvay settlements together reach roughly $3 billion.
Important: This page is attorney advertising and summarizes publicly reported litigation developments. It is not legal advice and does not create an attorney-client relationship. Settlement amounts, terms, and approval status may change as proceedings continue.